慢性乙型肝炎相关肝癌风险评估模型的研究新进展

摘要/Abstract

摘要： 肝细胞癌(HCC)是我国常见的恶性肿瘤之一,由多种病因导致,其中最主要的是乙型肝炎病毒(HBV)感染,抗病毒治疗可降低HBV感染者的肝癌发生率,但仍有一部分患者最终进展为肝癌,因此有必要对接受抗病毒治疗的HBV患者进行危险分层,识别出HCC高危人群。为解决这一问题,近年来学者们提出了许多肝癌风险预测模型,本文就这一研究进行简单论述。

康娅, 马金鑫, 戴光荣. 慢性乙型肝炎相关肝癌风险评估模型的研究新进展[J]. 肝脏, 2024, 29(2): 243-246.

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.
[2] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075.
[3] Wang C H, Wey K C, Mo L R, et al. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2015,16(9):3595-604.
[4] Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65:15-21.
[5] Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(9):1037-1048.
[6] Wong G L, Wong V W. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy[J]. World J Gastroenterol, 2013, 19(39):6515-6522.
[7] Wong V W, Chan S L, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers[J]. J Clin Oncol, 2010, 28(10):1660-1665.
[8] Yuen M F, Tanaka Y, Fong D Y, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B[J]. J Hepatol, 2009, 50(1):80-8.
[9] Wong G L, Chan H L, Wong C K, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol, 2014, 60(2):339-345.
[10] Yang H I, Yuen M F, Chan H L, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score[J]. Lancet Oncol, 2011, 12(6):568-574.
[11] Jung K S, Kim S U, Song K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy[J]. Hepatology, 2015, 62(6):1757-1766.
[12] Seo Y S, Jang B K, Um S H, et al. Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study[J]. Oncotarget, 2017, 8(68):113213-113224.
[13] Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4):800-806.
[14] Kim M N, Hwang S G, Rim K S, et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir[J]. Liver Int, 2017, (12):1788-1795.
[15] Kim J H, Kim Y D, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5):1066-1073.
[16] Yip T C, Wong G L, Wong V W, et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(5):847-854.
[17] Hsu Y C, Yip T C, Ho H J, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2):278-285.
[18] Kim S U, Seo Y S, Lee H A, et al. Validation of the CAMD score in patients with chronic hepatitis B virus infection receiving antiviral therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(3):693-699.
[19] Papatheodoridis G V, Sypsa V,et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(6):1088-1096.
[20] Yang H I, Yeh M L, Wong G L, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3):389-399.
[21] Sharma S A, Kowgier M, Hansen B E, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis[J]. J Hepatol, 2017, S0168-8278(17)32248-1.
[22] Åström H, Ndegwa N, Hagstr?m H. External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population[J]. JHEP Rep, 2021, 3(5):100343.
[23] Zhang H, Zhu J, Xi L, et al. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study[J]. World J Surg Oncol, 2019, 17(1):75.
[24] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等. 原发性肝癌的分层筛查与监测指南(2020版) [J]. 临床肝胆病杂志, 2021,37(2):286-295.
[25] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6):1368-1378.
[26] Yamashita Y, Joshita S, Sugiura A, et al. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C[J]. Hepatol Res, 2021, 51(9):933-942.
[27] Innes H, Jepsen P, McDonald S, et al. Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection[J]. JHEP Rep, 2021, 3(6):100384.
[28] Yang Y, Zhou Y, Zhang X, et al. Using the aMAP risk score to predict late recurrence following radiofrequency ablation for hepatocellular carcinoma in Chinese population: a multicenter study[J]. J Hepatocell Carcinoma, 2021, 8:837-850.
[29] Sun Y, Li Z, Liao G, et al. aMAP score as a predictor for long-term outcomes in patients with HBV-related acute-on-chronic liver failure[J]. Int J Gen Med, 2022, 15:407-415.
[30] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志,2022,38(2):288-303.
[31] Sohn W, Cho J Y, Kim J H, et al. Risk score model for the development of hepatocellular carcinoma in treatment-na?ve patients receiving oral antiviral treatment for chronic hepatitis B[J]. Clin Mol Hepatol, 2017, 23(2):170-178.

慢性乙型肝炎相关肝癌风险评估模型的研究新进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黎婉莹, 申笙, 刘诗, 孙剑. 血清HBV RNA在临床应用中尚未解决的关键科学问题[J]. 肝脏, 2024, 29(2): 143-146.
[2]	杨利平, 于杰, 李勤英, 夏艳, 齐高昂, 尚芮, 武龙君, 高磊. 超声引导下微波消融对复发性肝癌长期疗效的影响因素研究[J]. 肝脏, 2024, 29(2): 189-192.
[3]	张祥运, 马序竹, 于国英. 慢性乙型肝炎患者低病毒血症影响因素及管理策略研究[J]. 肝脏, 2024, 29(2): 247-250.
[4]	刘普, 卓红平, 陶光举. Gd-EOB-DTPA增强磁共振成像对乙型肝炎肝纤维化程度的评估[J]. 肝脏, 2024, 29(1): 47-49.
[5]	王大龙, 王涛, 王康娥. 瞬时弹性成像及血清HBsAg、HBV DNA联合评估乙型肝炎肝纤维化程度的价值[J]. 肝脏, 2024, 29(1): 56-59.
[6]	吕高燕, 王春娟. 血清HBeAg阳性慢性乙型肝炎患者接受核苷(酸)类似物治疗疗效和检测血清HBV RNA的意义[J]. 肝脏, 2024, 29(1): 77-80.
[7]	张莉莉, 甄飞. 组织内TRIM3及FoxO1表达与原发性肝癌患者病理特征及预后间的关系分析[J]. 肝脏, 2024, 29(1): 95-98.
[8]	马驰, 杨涓, 郑盛. 肠道菌群与肝脏疾病研究进展[J]. 肝脏, 2024, 29(1): 113-116.
[9]	刘敏, 李莉. 白细胞介素-6在原发性肝癌中的研究进展[J]. 肝脏, 2024, 29(1): 122-126.
[10]	张会, 李晓琴, 王成伟, 王蔚, 肖丽, 咸建春. 关于将慢性乙型肝炎纤维化分期中“advanced fibrosis”译为“进展期肝纤维化”的商榷[J]. 肝脏, 2023, 28(9): 1011-1011.
[11]	钟剑秋, 徐燕, 徐敏. 抗病毒治疗慢性乙型肝炎患者血清外泌体HBV-miR-3动态变化与病毒学指标的关系[J]. 肝脏, 2023, 28(9): 1044-1047.
[12]	蒋兆荣, 邹梅, 姬腾飞, 刘欢, 顾生旺, 冯伟广, 赵文玺. 核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效分析[J]. 肝脏, 2023, 28(9): 1048-1049.
[13]	顾达, 童聪, 王维钊, 向晓星, 赵祥安. 血清IL-10对慢性乙型肝炎患者抗病毒治疗后e抗原转阴的预测作用[J]. 肝脏, 2023, 28(9): 1053-1056.
[14]	殷琳琳, 吕慧, 王戊辰, 刘学进. 超声弹性成像检测肝脏、脾脏硬度值与血清肝纤维化指标对慢性乙型肝炎患者肝纤维化的评价[J]. 肝脏, 2023, 28(9): 1064-1067.
[15]	陈秀峰, 蒋丽萍, 沈玲. 中晚期肝癌患者应用TACE联合PMCT治疗的效果分析[J]. 肝脏, 2023, 28(9): 1068-1071.